This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

KEYTRUDA® (pembrolizumab) HNSCC Monotherapy Treatment Diary

Prescribing Information
Prescribing Information

This downloadable diary has been designed for HCPs like yourself, to provide your patients already on/or recently prescribed KEYTRUDA monotherapy for head and neck squamous cell carcinoma (HNSCC).

This diary contains information about KEYTRUDA monotherapy, including its method of administration, mode of action, possible side-effects and what the patient should do if they notice any signs or symptoms. It is also designed to support your consultations with a patient by providing space to record any questions the patient may have, record their future appointment dates and to help support the patient monitor adverse events and safety related issues.

Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.

More information about KEYTRUDA® (pembrolizumab)

Supporting documentation

GB-OHN-00214 | Date of Preparation: October 2020